Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that accounts for 60-70% of the 55 million worldwide dementia cases. The blood-brain barrier (BBB) acts as a mediator between the brain and cerebral vasculature, preventing the passage of deleterious substances, albeit significantly reducing drug delivery efficiency to the brain. The BBB is comprised of specialized cells that both maintain brain homeostasis and respond to pathological stress. Focused ultrasound-induced blood-brain barrier opening (FUS-BBBO) presents a noninvasive, transient, and targeted method to enhance drug delivery by locally increasing BBB permeability, in addition to modulating the neuroimmune landscape. This technique offers countless therapeutic opportunities for diseases of the brain, especially neurodegenerative disorders and AD.
Previous studies have demonstrated effective pathological amelioration and cognitive improvement by applying FUS-BBBO in severely progressed murine models of AD. However, growing interest in clinical translation of FUS-BBBO and in alternative, early intervention therapeutic paradigms necessitates a more thorough characterization of the role of FUS-BBBO in AD therapeutics, particularly at early disease states. This thesis focuses on characterizing three key elements of FUS-BBBO treatment for applications to AD therapy.
First, the physical effects of age and AD on the brain’s response to a single session of FUS-BBBO will be characterized. Next, the extent of cognitive and pathological improvement resulting from early intervention in male and female AD mice with repeated FUS-BBBO alone, then in combination with an amyloid-targeting therapeutic will be evaluated. Finally, the cell-specific response of astrocytes, oligodendrocytes, neurons and endothelial cells to FUS-BBBO will be characterized to elucidate the contribution of these cell types to previously observed cognitive and pathological improvements in male and female, young and aged, wild-type and AD mice.
Broadly, the findings of the work described herein will elucidate the role of FUS-BBBO in AD therapeutics. By defining the most important considerations for applying FUS-BBBO in aged and AD populations, characterizing the expected cognitive and pathological outcomes from early FUS-BBBO intervention, and characterizing a time course of cell-specific responses to elucidate the mechanisms that underlie these observations, these aims collectively seek to improve our understanding and optimize our use of FUS-BBBO for AD therapeutics.
| Identifer | oai:union.ndltd.org:columbia.edu/oai:academiccommons.columbia.edu:10.7916/fhwm-j597 |
| Date | January 2024 |
| Creators | Noel, Rebecca Lynn |
| Source Sets | Columbia University |
| Language | English |
| Detected Language | English |
| Type | Theses |
Page generated in 0.0018 seconds